Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Roche acquires digital diabetes management platform

Will integrate mySugr within its new patient-centred health services arm

Roche

Roche has acquired a smartphone-based diabetes management platform and will integrated it into its new patient-centred health services in diabetes care arm.

Apps and services from mySugr combine diabetes coaching, therapy management, unlimited test-strips and automated data tracking.

They can be integrated with a number of medical devices and Roche will keep it running as an open platform for all diabetes devices and services, irrespective of their manufacturer.

But the Swiss pharma firm will be keen to demonstrate to healthcare providers the benefits of using its Accu-Chek range of tools to improve therapy decisions and improve patient communication.

Roland Diggelmann, CEO of Roche Diagnostics, said: “We are excited about this agreement, as we will be able to offer seamlessly accessible patient solutions within an open platform to better respond to the unmet needs of people with diabetes. Our aim is to support people with diabetes to spend more time in their ideal glucose target range and improve their quality of life.

“Having partnered with mySugr since 2014, we see an excellent cultural fit, as both our companies are passionate about taking diabetes management to the next level and making a difference in managing diabetes.”

Founded in 2012, mySugr GmbH has offices in San Diego and Vienna, and more than one million users globally.

Frank Westermann, mySugr’s CEO and co-founder, said: “We started mySugr to solve our everyday problems and simplify diabetes therapy through smartphones.

“The mySugr team has filled a gap for over a million loyal users so far, and with Roche’s diabetes expertise and global network, mySugr will become an indispensable companion for hassle-free life.”

Roche, which was an early investor in the platform through its Roche Venture Fund, has now acquired all shares of mySugr GmbH and plans to keep it as a separate legal entity.

Article by
Dominic Tyer

4th July 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics